DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Constantino"


25 mentions found


☆ Moderna teams up with IBM to put AI, quantum computing to work on mRNA technology used in vaccines
  + stars: | 2023-04-20 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Moderna and IBM are teaming up to use generative artificial intelligence and quantum computing to advance mRNA technology, the development at the core of the company's blockbuster Covid vaccine, the companies announced Thursday. The companies said they signed an agreement for Moderna to access IBM's quantum computing systems. IBM will also provide experts who can help Moderna scientists explore the use of quantum technologies, the companies added. Unlike traditional computers, which store information as either zeroes or ones, Quantum computing hinges on quantum physics. The companies said Moderna will use IBM's model to understand "the characteristics of potential mRNA medicines" and design a new class of vaccines and therapies.
☆ A new long Covid treatment shows promise, but insurance won't cover it and some doctors are skeptical: Here's why
  + stars: | 2023-04-20 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +7 min
Some long Covid patients swear by the treatment, with one describing it to CNBC Make It as a "total game changer." That's a huge stumbling block for many medical experts, who caution against viewing it as a universal remedy for long Covid. Most of the ones who do get treated have reported improved long Covid symptoms, the clinic adds. That's because a variety of underlying physiological conditions — like chronic lung issues, for example — can "drive different manifestations of long Covid," says Dr. Lucy Horton, an infectious disease physician who founded the long Covid clinic at UC San Diego Health. "For many [Covid] long haulers, including myself, financial freedom is gone because we can't work full-time."
☆ Abbott Labs shares pop as revenue, earnings defy steep drop in Covid test sales
  + stars: | 2023-04-19 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Shares of Abbott Laboratories popped Wednesday after the company's earnings and revenue topped Wall Street's expectations, defying a dramatic slowdown in sales of its Covid-19 tests. Abbott reported revenue of $9.7 billion for the first quarter, slightly surpassing the Refinitiv estimate of $9.64 billion due to recovery in its medical devices business. Strong sales in Abbott's medical devices business fueled the company's first-quarter beats. The unit raked in $3.9 billion in sales during the quarter, up nearly 9% from the same period last year. That comes after rival Johnson & Johnson reported strong growth in its own medical devices unit, noting that surgical procedures are "well in recovery."
☆ Johnson & Johnson expects no new Covid vaccine revenue, after shots drive earnings beat
  + stars: | 2023-04-18 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
International Covid vaccine sales helped spark Johnson & Johnson 's revenue and earnings beat on Tuesday, but the company said it expects no sales from the shot moving forward. That marks the end of a rocky three years for J&J's Covid vaccine despite being one of the first shots to enter the U.S. market during the pandemic. Notably, all Covid vaccine revenue during the quarter came from outside of the U.S. JP Morgan analyst Chris Schott added that J&J's first-quarter beat was in part "driven by Covid vaccine upside." While J&J's vaccine fell out of favor in the U.S. and other wealthy countries, developing countries have continued to rely on it.
☆ Johnson & Johnson (JNJ) earnings Q1 2023
  + stars: | 2023-04-18 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +5 min
Johnson & Johnson shares fell Tuesday after the company reported adjusted earnings and revenue that topped Wall Street's expectations, but lowered its sales guidance for its pharmaceutical business. J&J is now forecasting 2023 sales of $97.9 billion to $98.9 billion, about $1 billion higher than the guidance provided in January. Lawsuits allege the company's talc products were contaminated with the carcinogen asbestos, which caused ovarian cancer in thousands of individuals. Some suits link several deaths to J&J's talc products. Read the full J&J earnings report.
☆ Moderna shares fall despite promising data from cancer vaccine trial
  + stars: | 2023-04-17 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Shares of Moderna fell Monday as Wall Street chewed over new trial results on the personalized cancer vaccine it is developing with Merck . Those results, presented at an American Association for Cancer Research meeting in Florida, add to the initial results on the treatment combination released in December. Analysts from SVB Securities said the results suggest the personalized cancer vaccine shows promise. Wells Fargo analyst Mohit Bansal also said he's expressing "cautious optimism" about the treatment combination. In a Sunday note, Bansal pointed to "trial imbalances" that potentially produced more favorable results for the personalized cancer vaccine.
☆ Abortion providers rush to make backup plans as Supreme Court decides whether to keep limits on mifepristone
  + stars: | 2023-04-14 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +6 min
Some in-person clinics in New York, California and Kansas will offer mifepristone for now, but are preparing to provide an alternative abortion pill if a subsequent decision essentially bans the drug. U.S. abortion pill providers are scrambling to make backup plans as the Supreme Court decides whether to keep restrictions on the key drug mifepristone. Those restrictions will limit access to mifepristone even in states where abortion is legal. Some in-person abortion clinics in states where the procedure is legal told CNBC that operations will remain largely the same. Other clinics in states where abortion is legal can prescribe mifepristone off-label beyond the first seven weeks of pregnancy, according to Hill.
☆ Blocking FDA approval of abortion pill could stifle innovation in the biopharma industry, experts say
  + stars: | 2023-04-13 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +6 min
A messy legal fight over the Food and Drug Administration's approval of the abortion pill mifepristone poses risks to the biopharma industry that go beyond the single drug. If a subsequent decision tosses out the pill's approval, it could potentially stifle innovation in the sector and deter investments in the development of life-changing drugs, biopharma companies and experts in law and economics say. More than 200 biopharma companies made a similar claim Monday in an open letter calling for the reversal of Kacsmaryk's decision. But Hastings said biopharma companies still respect the FDA when the agency turns down their drugs. Suliman offered a more hopeful take on how the legal fight could affect biopharma innovation.
☆ Florida House passes six-week abortion ban backed by DeSantis
  + stars: | 2023-04-13 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +5 min
The Florida House of Representatives on Thursday passed legislation that would ban most abortions after six weeks, when many women don't know they are pregnant. The bill would only take effect if the state's existing 15-week ban is upheld in an ongoing legal challenge that is before the state Supreme Court. "Today we stand for life, we stand with mothers, and we stand with Florida families," said Persons-Mulicka. A recent survey suggests the six-week abortion ban isn't popular among Florida residents. The Biden administration will ask the Supreme Court to intervene, Attorney General Merrick Garland announced Thursday.
☆ House Democrats call for immediate hearing on Texas abortion pill ruling
  + stars: | 2023-04-12 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Abortion rights advocates gather in front of the J Marvin Jones Federal Building and Courthouse in Amarillo, Texas, on March 15, 2023. Democrats on the U.S. House Committee on Energy and Commerce on Wednesday requested an immediate hearing on a federal judge's order suspending the Food and Drug Administration's approval of the abortion pill mifepristone. All 23 Democrats on the committee wrote in a letter to Chair Cathy McMorris Rodgers, R-Wash., arguing that the ruling undermines the FDA's authority over the drug approval process. They alleged that the FDA failed to follow Congress' "statutorily prescribed drug approval process" by approving mifepristone in 2000. "The FDA's lawless actions ultimately endanger women and girls seeking chemical abortions," the lawmakers wrote.
☆ Juul to pay $462 million to settle youth vaping claims from six states, D.C.
  + stars: | 2023-04-12 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Juul will pay $462 million to settle claims by six states and Washington D.C. that the vaping company marketed its addictive e-cigarettes to underage teens, five Democratic attorneys general announced Wednesday. The states that reached the settlement with Juul are New York, California, Massachusetts, New Mexico, Illinois and Colorado. New York will get $112.7 million over an eight-year period, which will support underage vaping abatement programs across the state. The FDA also ordered Juul to stop selling its vaping products last June. It added that youth use of tobacco products in any form is unsafe.
☆ Abortion pill alternative: The drug that could be used if Texas ban on mifepristone upheld
  + stars: | 2023-04-11 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
A federal judge's ruling could take the abortion pill mifepristone off the market — but there is another medication that could provide an alternative for people seeking to terminate their pregnancies. Two states in reaction to that ruling already are stockpiling supplies of misoprostol, the drug that doctors typically prescribe with mifepristone to induce an abortion. That leaves misoprostol available as a safe and effective treatment for women who want to end their pregnancies. Some U.S. abortion providers are prepared to offer misoprostol as a stand-alone treatment, according to Jenny Ma, senior staff attorney at the Center for Reproductive Rights, a legal advocacy group that represents abortion providers worldwide. A study released in February by abortion researchers at the University of Texas in Austin found that misoprostol was 88% effective at causing an abortion.
☆ Moderna says it expects up to $15 billion in sales of Covid, RSV, flu vaccines in 2027
  + stars: | 2023-04-11 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +1 min
Moderna on Tuesday said it expects to see between $8 billion and $15 billion in sales from its Covid, RSV, flu and other respiratory vaccines in 2027. The biotech company said it sees a corresponding operating profit in the range of $4 billion to $9 billion. Those respiratory product estimates are supported by additional research investments of $6 billion to $8 billion "over the next few years," Moderna added. Moderna said earlier this year it expects $5 billion in mRNA Covid vaccine sales in 2023, a steep drop from the $18 billion the shot raked in last year. The Cambridge, Massachusetts-based company's Covid vaccine remains its only commercially available product.
☆ Moderna says it hopes to offer new vaccines for cancer, heart disease, and other conditions by 2030
  + stars: | 2023-04-10 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
Moderna hopes to offer a new set of life-saving vaccines targeting cancer, heart disease and other conditions by 2030, a spokesperson for the company told CNBC on Monday. "It can be applied to all sorts of disease areas; we are in cancer, infectious disease, cardiovascular disease, autoimmune diseases, rare disease." Burton's remarks also come ahead of Moderna's Vaccine Day on Tuesday. He highlighted Moderna's personalized cancer vaccine, a highly anticipated mRNA shot being developed to target different tumor types. In February, the Food and Drug Administration granted Breakthrough Therapy Designation to Moderna's personalized cancer vaccine in combination with Merck's immunotherapy drug Keytruda for patients with a deadly form of skin cancer called melanoma.
☆ Pfizer CEO signs letter in support of FDA after federal judge suspends approval of abortion pill
  + stars: | 2023-04-10 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Pfizer 's CEO signed on to an industry letter in support of the Food and Drug Administration's authority to regulate drugs after a federal judge in Texas suspended the agency's approval of the abortion pill mifepristone. Albert Bourla was among the more than 200 pharmaceutical company executives who signed the letter after U.S. Judge Matthew Kacsmaryk's controversial ruling on Friday. Kacsmaryk sided with an anti-abortion group, arguing that the FDA rushed its approval process and violated federal standards. Kacsmaryk's decision conflicts with a ruling by a federal judge in Washington state. The dueling orders by two federal judges create a complicated legal standoff that could potentially escalate to the Supreme Court.
☆ Alzheimer’s patients retain the benefits of Leqembi even when they stop the drug, Eisai says
  + stars: | 2023-04-06 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
Alzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai shows. The findings also come as Eisai and Biogen try to regain their footing after the polarizing approval and disastrous rollout of its other Alzheimer's disease therapy, aduhelm, last year. In the analysis, Alzheimer's patients stopped taking Leqembi after 18 months in a phase two clinical trial and later resumed the treatment in an extension trial. Amyloid is a protein that builds up on the brain in Alzheimer's patients and disrupts cell function. That means Alzheimer's disease progressed at a slower rate in patients who received Leqembi compared to those who took the placebo during the clinical trial.
☆ Carl Icahn says Illumina’s appeal of FTC order to divest Grail is ‘an almost impossible battle’
  + stars: | 2023-04-05 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Carl Icahn on Wednesday said Illumina 's efforts to appeal a Federal Trade Commission order to divest the highly contested Grail acquisition "is an almost impossible battle." Illumina on Monday told CNBC it intends to appeal the FTC's order in federal court, and will seek an expedited decision. The FTC's order reverses an administrative judge's September ruling, which dismissed the commission's initial challenge to the Grail deal. The company last year appealed a similar order by European Union regulators to unwind the Grail deal. The company on Wednesday said in a statement to CNBC that it has a "strong case on appeal" of the FTC's order.
☆ Eli Lilly says experimental Alzheimer's drug reduces brain plaque in early study
  + stars: | 2023-04-05 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
Eli Lilly 's experimental Alzheimer's drug lowered levels of brain plaque in patients who are in the earliest stages of the devastating disease, initial data shows. Researchers have argued that accumulation of amyloid plaque is a crucial first step toward the cognitive decline observed in Alzheimer's disease. The early data comes as Eli Lilly continues its decades-long bid to bring an Alzheimer's drug to the market. Eli Lilly found the drug caused a "rapid and robust" clearance of amyloid plaque, the presentation said. But Tewari said it's unclear if clearing amyloid plaque will lead to clinical benefits like a reduction in cognitive decline.
☆ Johnson & Johnson shares rise after company proposes baby powder cancer settlement
  + stars: | 2023-04-05 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Johnson & Johnson shares on Wednesday climbed after the company proposed paying $8.9 billion to settle thousands of claims that its baby powder and other talc products caused cancer. The pharmaceutical giant also said its subsidiary LTL Management refiled for Chapter 11 bankruptcy protection after its first attempt faced legal challenges. JPMorgan analyst Chris Schott on Thursday called the proposed settlement a positive for the company in a note. The proposed $8.9 billion settlement is also in-line with JPMorgan's $8 billion to $10 billion estimate, Schott noted. It's also unclear whether the proposed settlement will win approval in bankruptcy court, Bank of America analyst Geoff Meacham noted Thursday.
☆ J&J will pay $8.9 billion to settle claims cosmetic talc products caused cancer
  + stars: | 2023-04-04 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +1 min
Containers of Johnson's baby powder made by Johnson and Johnson are displayed on a shelf on July 13, 2018 in San Francisco, California. Johnson & Johnson on Tuesday said it will pay $8.9 billion over the next 25 years to settle allegations that the company's baby powder and other talc products caused cancer. The company ended sales of its talc-based baby powder globally in 2023 after it faced thousands of lawsuits from customers claiming its talc products caused cancer due to contamination with a carcinogen called asbestos. J&J spun off subsidiary LTL management in October 2021 in a bid to reduce its losses from litigation and settlement. The company funneled its talc lawsuits to the subsidiary and declared it bankrupt.
☆ Frank founder criminally charged with fraud over $175 million JPMorgan deal
  + stars: | 2023-04-04 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +1 min
The Justice Department on Tuesday charged Charlie Javice, founder of college financial planning platform Frank, with defrauding JPMorgan Chase of $175 million. The one-rising tech star – who was once named as one of Forbes' 30 Under 30 – was arrested Monday night in New Jersey and is expected in court Tuesday afternoon. They include one count of conspiracy to commit bank and wire fraud, one count of wire fraud affecting a financial institution, one count of bank fraud and one count of securities fraud. The Securities and Exchange Commission on Tuesday also sued Javice for fraud in connection with the alleged scheme. The charges come months after JPMorgan filed a lawsuit against Jarvice alleging she duped the bank into believing Frank had more than four million customers.
☆ FTC orders Illumina to divest $7.1 billion acquisition of cancer test developer Grail
  + stars: | 2023-04-03 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
The Federal Trade Commission on Monday ordered Illumina to divest its controversial acquisition of cancer test developer Grail, saying the deal would stifle competition and innovation. The decision reverses an administrative judge's September ruling, which dismissed the FTC's initial challenge to the $7.1 billion deal. Illumina said in a statement that it intends to appeal the FTC's decision in federal court and will seek an expedited decision. "The acquisition of GRAIL potentially gives Illumina incentives to favor GRAIL over its rivals by providing GRAIL preferential access or preferential terms for acquiring NGS inputs," the FTC said. Illumina also "stands to earn substantially more profit on the sale of GRAIL tests than it does by supporting rival test developers," the commission added.
☆ Carl Icahn blasts Illumina for nearly doubling CEO’s pay despite steep drop in market value
  + stars: | 2023-03-31 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +1 min
Carl Icahn blasted Illumina for nearly doubling its CEO's pay last year despite a dramatic drop in the biotech company's market value since closing a controversial deal. He was awarded nearly $26.8 million in total pay last year, nearly double the $14.3 million he received in 2021, according to a preliminary proxy statement Illumina filed Thursday. Part of deSouza's pay bump is a special grant of stock options worth $12.5 million, which Illumina called a "meaningful retention incentive in a highly competitive talent environment." DeSouza's pay increase follows a rocky 18 months for San Diego-based Illumina. The company's market value has fallen to roughly $35 billion from about $75 billion in August 2021, the month it closed its acquisition of cancer test developer Grail.
☆ Illumina urges shareholders to reject Carl Icahn's board nominees as proxy fight heats up
  + stars: | 2023-03-30 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +1 min
Illumina on Thursday urged shareholders to reject Carl Icahn's three board nominees at this year's annual meeting, saying they would "threaten the progress" of the biotech company's core business. "Carl Icahn's involvement with Illumina risks the long-term success of the Company, and his director nominees bring no relevant skills to the Board of Directors," San Diego-based Illumina said in a preliminary proxy statement filed Thursday. The DNA sequencing company told shareholders to discard any proxy card sent by the activist investor or his affiliate entities. Illumina also urged shareholders to vote in favor of its proposed board of directors, noting that it would mail its definitive proxy materials soon. Illumina said it will provide more information about "the strength of our Board and management team, our strategy to deliver shareholder value – with innovation at its core – and the potential for Mr. Icahn's associate nominees to damage that strategy."
☆ J&J backs out of RSV vaccine race with rivals Pfizer and GSK
  + stars: | 2023-03-29 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Johnson & Johnson on Wednesday said it's ducking out of the RSV vaccine race, weeks after competitors Pfizer and GSK inched closer to launching the world's first shot against the deadly virus. J&J will stop working on its investigational RSV adult vaccine program and discontinue a pivotal phase three trial testing the shot, the company announced in a press release. Since then, the race to create the world's first RSV vaccine has garnered more attention than ever. A phase two trial on the company's RSV shot found it provided 80% protection against severe RSV infections. Drugmaker Moderna also has its own potential RSV shot, which performed well in clinical trials.
<< prev 14 next >>
Total: 25